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The impact of vitamin D pathway genetic
variation and circulating 25-hydroxyvitamin D
on cancer outcome: systematic review and
meta-analysis
P G Vaughan-Shaw1, F O’Sullivan2, S M Farrington1, E Theodoratou1,3, H Campbell1,3, M G Dunlop1
and L Zgaga*,2
1MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH42XU, UK;
2Department of Public Health and Primary Care, Trinity College Dublin, Dublin 24, Republic of Ireland and 3Centre for Population
Health Sciences, University of Edinburgh, Edinburgh EH164UX, UK
Background: Vitamin D has been linked with improved cancer outcome. This systematic review and meta-analysis investigates the
relationship between cancer outcomes and both vitamin D-related genetic variation and circulating 25-hydroxyvitamin D (25OHD)
concentration.
Methods: A systematic review and meta-analysis of papers until November 2016 on PubMed, EMBASE and Web of Science
pertaining to association between circulating vitamin D level, functionally relevant vitamin D receptor genetic variants and variants
within vitamin D pathway genes and cancer survival or disease progression was performed.
Results: A total of 44 165 cases from 64 studies were included in meta-analyses. Higher 25OHD was associated with better overall
survival (hazard ratio (HR¼ 0.74, 95% CI: 0.66–0.82) and progression-free survival (HR¼ 0.84, 95% CI: 0.77–0.91). The rs1544410
(BsmI) variant was associated with overall survival (HR¼ 1.40, 95% CI: 1.05–1.75) and rs7975232 (ApaI) with progression-free survival
(HR¼ 1.29, 95% CI: 1.02–1.56). The rs2228570 (FokI) variant was associated with overall survival in lung cancer patients (HR¼ 1.29,
95% CI: 1.0–1.57), with a suggestive association across all cancers (HR¼ 1.26, 95% CI: 0.96–1.56).
Conclusions: Higher 25OHD concentration is associated with better cancer outcome, and the observed association of functional
variants in vitamin D pathway genes with outcome supports a causal link. This analysis provides powerful background rationale to
instigate clinical trials to investigate the potential beneficial effect of vitamin D in the context of stratification by genotype.
The importance of vitamin D for bone health is well established,
but the role of vitamin D beyond the skeletal system has been
under debate for decades (Theodoratou et al, 2014). In recent
years, it has become apparent that the vitamin D receptor (VDR) is
expressed in most cells, and that multiple tissues have the ability to
convert the primary circulating form of vitamin D into the active
form (Bouillon et al, 2013), implying that extra-skeletal effects of
vitamin D are likely.
While typically thought of as ‘vitamin’, it may be more
appropriate to regard the primary circulating form, 25-hydro-
xyvitamin D (25OHD), as a pre-hormone and the primary active
form, 1,25-dihydroxyvitamin D (1,25(OH)2D), as a hormone.
It has been previously recognised that mutations in genes involved
in response to hormones, their metabolism or actions may affect
the prognosis of disease and thus act as modifiers. Correspond-
ingly, 1,25(OH)2D binds to the VDR (a ligand-dependent
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transcription factor) and polymorphisms in the VDR gene have
been shown to modify the activity of this VitD–VDR complex
(Anderson et al, 2003): for example, rs11568820 is situated in the
VDR promoter region and can influence transcriptional activity
(Yamamoto et al, 1999), while rs2228570 affects the translational
start site (Uitterlinden et al, 2004). Therefore, it is hypothesised
that not only vitamin D status but also expression and structure of
VDR determine molecular actions, and can potentially modify
cancer risk and survival (Flugge et al, 2007; Li et al, 2007; Zgaga
et al, 2014). The VitD–VDR complex has the ability to exert
downstream biological effects; amongst others, it can regulate the
expression of multiple target genes, including several with anti-
tumour properties (Ramagopalan et al, 2010). Moreover, poly-
morphisms in the VDR gene have been linked to cancer risk,
including prostate (Taylor et al, 1996), breast (Lowe et al, 2005),
skin and bowel (Ingles et al, 2001; Xu et al, 2014; Serrano et al,
2016), and VDR expression has been linked to survival in prostate
and breast cancer (Berger et al, 1991; Hendrickson et al, 2011;
Ditsch et al, 2012). Unlike highly variable environmental exposures
(sunlight, diet and supplements) or seasonally varying 25OHD
levels (Kelly et al, 2015), genetic variants are constant, present since
conception and cannot be modified by the disease; thereby
removing reverse causation concerns.
Three aspects further strengthen the case for understanding the
associations between vitamin D and cancer outcomes: first, cancer
incidence and mortality are increasing (CRUK, 2015); second,
vitamin D deficiency is common worldwide among otherwise
healthy individuals (Holick, 2007; Zgaga et al, 2011), and
particularly among cancer patients (Crew et al, 2009; Fakih et al,
2009; Shanafelt et al, 2011; Vrieling et al, 2011; Zgaga et al, 2014),
and third, vitamin D deficiency is a modifiable risk factor; based on
the studies that report an association between vitamin D deficiency
and poorer cancers outcomes. Unsurprisingly, it has been proposed
that vitamin D may have potential value as an adjuvant
chemotherapeutic agent, particularly since vitamin D supplements
are cheap, safe and readily available (Newton-Bishop et al, 2009,
2015; Drake et al, 2010; Hatse et al, 2012; Zgaga et al, 2014).
Here we present a systematic review and meta-analysis
examining the role of vitamin D on cancer progression and
survival. We conducted a comprehensive evaluation of the
literature that examines the associations between cancer outcomes
and genetic factors involved in the vitamin D pathway, in addition
to circulating 25OHD concentration. Focus on vitamin D-related
genetic variation allowed us to partially mitigate against potential
confounding or reverse causation, biases that typically limit
implications of findings from observational vitamin D studies.
MATERIALS AND METHODS
Literature search. We performed a systematic literature review
and meta-analysis following PRISMA guidelines (Moher et al,
2009). The electronic databases PubMed (NCBI, 2015), EMBASE
(EMBASE, 2015), and Web of Science (JISC, 2015) were searched
up to week 3, November 2015. We searched for studies that
examined the association between cancer outcomes and
(i) measured vitamin D levels and (ii) genetic factors known to
affect vitamin D metabolism or pathways. A list of search terms
was compiled using a number of core papers in the field. For
cancer outcomes, we included a combination of terms: cancer,
neoplasm, malignant, malignancy with survival, outcome, prog-
nosis, mortality, death, recurrence. For vitamin D levels, we
included terms: 25-hydroxyvitamin D, calcidiol and 25OHD; for
vitamin D receptor, and for commonly studied variants, we
searched for: vitamin D receptor, VDR, rs1544410, BsmI,
rs10735810, rs2228570, FokI, rs7975232, ApaI, rs11568820, Cdx-
2, rs2282679, rs12785878, rs10741657 and rs6013897. Finally, we
also included variation in genes related to vitamin D synthesis,
transport or metabolism: 1-a-hydroxylase, CYP27B1, 25-hydro-
xylase, CYP2R1, 24-hydroxylase, CYP24A1, vitamin D binding
protein, 27-hydroxlyase and CYP27A1. Genetic variants beyond
those explicitly searched for were only included if previously
shown to affect vitamin D metabolism. We considered all human
research full text articles, with no restriction on language or article
type. Bibliographies of retrieved papers and previous reviews were
hand-searched to identify other relevant studies.
Selection criteria and selection of relevant studies. Study
inclusion ‘PICO’ criteria were as follows: (i) participants:
individuals of any age who received a diagnosis of cancer; (ii)
intervention/Exposures: assessment of vitamin D status or genetic
factors known to affect vitamin D concentration, metabolism or
pathways; (iii) comparators: study reports a quantitative associa-
tion between cancer outcome and either vitamin D status (e.g.,
concentration, quartiles, low/high levels) sampled at most 1 year
prior to the diagnosis, or any germline genetic variation or gene
expression in normal tissue; and (iv) Outcome: cancer-specific or
all-cause mortality, or disease progression (e.g., disease-free
survival, local recurrence or metastasis). Observational retro-
spective and prospective cohorts were included.
In relation to patients, exclusion criteria were: (i) pre-cancerous
lesions, and (ii) mixed-cancer cohort without site-specific reporting;
in relation to exposures: (iii) vitamin D intake and supplementation,
(iv) acquired non-germline mutations or tumour gene expression,
and (v) predicted vitamin D status; in relation to outcomes: (vi)
prognostic markers such as Prostate Specific Antigen or Breslow
thickness, (vii) population cancer mortality rates; in relation to
study/publication type: (viii) ecological studies, and (ix) reviews,
editorials, case reports, conference abstracts and nonclinical
publications. If the same patient cohort was reported on more than
once, we used the highest quality, largest sample size or most recent
publication. Article titles and abstracts were screened for eligibility,
independently by two authors (PVS and LZ or FOS). Disagreements
were resolved by discussion and review of full text.
Data extraction. The data extraction was performed by a single
investigator (PVS or FOS) using the predefined data fields and
extraction was cross-checked by a second investigator in its
Box 1. Conversion of continuous HR and 95% CI
estimate to per 10ngml1 HR estimates.
To achieve this, we raised the continuous HR (or ‘HR per 1 ngml 1’) to the
power of 10 to get [A], per 10 ngml 1 HR (e.g., continuous HR, 0.89, hence
per 10 ngml 1 HR: 0.89^10¼0.3118). In order to calculate the confidence
intervals we first found the exp(s.e.(beta))¼ [B]; the standard errors (s.e.)
were calculated using the formula below. We then calculated 1.96*(x
xbar)¼ [C], where x was fixed at 10 ngml 1 and xbar was the median of all
cohort means from the rest of the studies included in the meta-analysis. We
found this to be 23 ngml 1, therefore 1.96*(10 23)¼  25.872¼ [C]. [B]
was then raised to the power of [C], to get [D]. Finally, the HR per
10 ngml 1 [A] was multiplied or divided by [D] in order to derive the upper
and lower 95% confidence intervals. Therefore, the resulting HR was A and
95% CI: (A*D) to (A/D).
(Continuous HR)^10¼ [A]¼ per 10 ng/ml HR
SE¼ log upper 95% CIð ÞlogðHRÞ
1:96
exp(s.e.(beta))¼ [B]
1.96*(x xbar)¼ [C]
B^C¼ [D]
A*D¼ lower 95% CI
A/D¼ upper 95% CI.
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entirety (FOS or PVS). The data from eligible studies were
extracted using a tailored data extraction form that included the
following information: first author, publication year, location or
ethnicity of patients, sample size, mean age, gender, cancer site
(subtype/histology where relevant), cancer stage, any interventions
(e.g., chemotherapy), vitamin D exposure studied and important
meta-data (time of sampling, mean/median 25OHD values or
range for categories being compared; SNP position, name and rs
ID, genotypes compared and model: additive, recessive or
dominant), covariates considered, details of outcomes studied,
Initial search
WOK
N =1937
EMBASE
N =1502
N =2570
(1769 duplicates removed)
3070 records screened by title and/or abstract
(28 duplicates removed )
100 full-text articles considered for inclusion
and assessed for eligibility
81 articles included in the
qualitative synthesis
64 articles included
in the meta-analysis
Exposure*
Articles
reporting
250HD
N =41
Articles
reporting
genetic factors
N =27
Articles reporting
disease
progression
N =33
Articles
reporting
survival
N =55
Outcome*
Excluded (N =19)
1 case-control study
1 used predicted 250HD level
1 described an outgoing study
1 used only marker of recurrence(PSA)
2 used tumour clinicopathological features
as marker of outcome
3 reported overall cancer mortality in
population or unspecified cancer cohorts
4 used population cohort and 250HD was
measured >1 year pre-diagnosis
6 used expression in tumour cells
Not included in meta-analysis (N =17)
13 did not report HR †
2 used same cohort ¥
1 used serial 250HD measurements
1 used circulating DBP levels§
100 bibliographies screened
18 new abstracts read
No additional articles identified
N =528
(684 duplicates removed)
PubMed
N =900
WOK
N =498
EMBASE
N =480
PubMed
N =234
2970 records excluded
Search update
Figure 1. PRISMA Flowchart of the study selection process. Two studies used the same prostate cancer cohort but one reported on circulating
25OHD and the other on genetic variants, and so both were retained. (Holt et al, 2010, 2013) Three publications used the same initial cohort of
lung cancer patients but two reported on different subpopulations of patients (according to disease stage) and so were retained, (Zhou et al, 2007;
Heist et al, 2008), while a third reported on different exposures to the first two and so was also retained (Zhou et al, 2006). Finally, four studies
reported on the same melanoma patient cohort (Newton-Bishop et al, 2009, 2015; Field et al, 2013; Davies et al, 2014) (one paper scored lower in
NOS scoring was excluded (Field et al, 2013), while the remaining three, which reported different exposure or outcomes were retained. yOnly a
single study reported impact of circulating vitamin D-binding protein levels on outcome and so could not be included in the meta-analysis.
*Includes only exposures and outcomes included in MA. Articles may report on multiple exposure-outcome pairs hence the sum of the pairs is
greater than the number of articles included. For example, several papers studied the effect of more than one SNP for example, Zgaga et al,
(Zgaga et al, 2014), while many papers studied the impact on both overall survival or progression-free survival for example, Lohman et al (Lohmann
et al, 2015). However, where multiple estimates were extracted, no patient was included more than once for a certain exposure or outcome. w
Study authors were contacted to provide HR, RR or OR when not reported; 13 did not respond. f One study (Vrieling et al, 2011) used the same
breast cancer cohort as a later, larger study (Vrieling et al, 2014) and as both had the same NOS score, the newer study was included. 25OHD: 25-
hydroxyvitamin D; DBP: vitamin D binding protein; HR: hazard ratio; PSA: prostate specific antigen; WOK: Web of Knowledge.
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Table 1. Characteristics of studies (N¼64) included in the meta-analysis
Variable Outcome
First author, year
Cancer
(subtype) HR/OR
Sample
Size Site
Follow-
up (m) Events NOS 25OHD Genetic
Progr-
ession Survival
Anic et al (2012) Brain (glioma) HR 320 USA 28 248 cancer deaths 5 | CS
Lim et al (2015) Breast HR 491 Korea 86 32 recurrences; 22
cancer deaths
8 | BT DFS CS
Lohmann et al (2015) Breast HR 934 Canada 112 Not given 4 | BT RFS OS
Clark et al (2014) Breast HR 82 USA 436 23 relapses or deaths 5 | BT RFS
Vrieling et al (2014) Breast HR 2177 Germany 64 206 cancer deaths,
241 recurrences or
deaths
7 | 66% BT DFS CS
Mishra et al (2013) Breast OR 232 USA NA Not given 5 | DFS
Pande et al (2013) Breast HR 1029 USA 114 266 recurrences or
deaths
6 | DFS
Perna et al (2013a) Breast HR 498 Germany 60 48 cancer deaths 7 | CS
Villasenor et al (2013) Breast HR 585 USA 110 48 cancer deaths 7 | AT CS
Hatse et al (2012) Breast HR 1800 Belgium 56 118 relapses; 64
cancer deaths
5 | BT DFI CS
Jacobs et al (2011) Breast OR 512 USA 88 Not given 5 | AT R OS
Kim et al (2012) Breast HR 310 Korea 23 33 metastases or
deaths
7 | BT DFS
Goodwin et al (2009) Breast HR 512 Canada 139 116 recurrences; 106
deaths
7 | BT R OS
Goode et al (2002) Breast HR 721 UK NA 200 deaths 6 | OS
Lundin et al (1999) Breast RR 111 Sweden 67 44 deaths 4 | OS
Tretli et al (2012) Breast, colon, lung, and
lymphoma
HR 658 Norway 460 343 cancer deaths 7 | BT CS
Wesa et al (2015) Colorectal HR 250 USA NA 153 deaths 5 | BT OS
Zgaga et al (2014) Colorectal HR 1598 UK 107 363 cancer deaths 8 | AT | CS
Perna et al (2013b) Colorectal HR 1397 Germany 60 336 cancer deaths 6 | CS
Szkandera et al (2013) Colorectal HR 264 Austria 53 45 recurrences 5 | R
Fedirko et al (2012) Colorectal HR 1202 Europe 73 444 cancer deaths 8 | BD | CS
Ng et al (2011) Colorectal HR 515 USA 61 440 progression; 475
deaths
5 | BT TTP OS
Mezawa et al (2010) Colorectal HR 257 Japan 32 30 cancer deaths;
recurrences not given
5 | NS DFS CS
Ng et al (2008) Colorectal HR 304 USA 78 96 cancer deaths 7 | BD CS
Ren et al (2012) Gastric HR 197 China 460 106 deaths 5 | BT OS
Lee et al (2014) Haematological (AML) HR 97 USA 16 55 relapses; 51
deaths
4 | BT R OS
Shanafelt et al (2011) Haematological (CLL) HR 543 USA 118 201 progression; 96
deaths
8 | NS TTT OS
Aref et al (2013) Haematological (CLL,
NHL)
HR 195 Egypt 60 118 deaths 5 | BT OS
Drake et al (2010) Haematological
(DLBCL)
HR 983 USA 35 404 events; 168
cancer deaths
6 | 66% BT EFF CS
Pardanani et al (2011) Haematological (PMF,
MDS)
HR 321 USA 34 36 progression; 171
deaths
4 | BT LFS OS
Bittenbring et al (2014) Haemotological (BCL) HR 359 Germany 49 Not given 4 | AT EFF OS
Kelly et al (2015) Haemotological (FL) HR 423 USA 65 193 progression; 58
deaths
5 | BT PFS OS
Azad et al (2013) Head and neck HR 522 Canada 453 214 deaths 8 | OS
Zeljic et al (2012) Head and neck OR 110 Serbia 28–100 Not given 5 | CS
Meyer et al (2011) Head and neck HR 540 Canada 96 119 recurrences; 223
deaths
8 | BT R OS
Gugatschka et al (2011) Head and neck (SCC) RR 88 Austria NA 31 progression; 29
deaths
4 | BT DFS OS
Hama et al (2011) Head and neck (SCC) HR 204 Japan 34 103 progression or
deaths
6 | DFS
Finkelmeier et al (2014) Liver (HCC) HR 200 Germany 11 60 deaths 6 | BT OS
Zhou et al (2007) Lung HR 447 USA 72 126 cancer deaths 7 | BT CS
Liu et al (2011) Lung (AC, SCC) HR 568 China 19 311 deaths 6 | NS | OS
Heist et al (2008) Lung (AC, SCC) HR 294 USA 42 233 deaths 6 | NS | OS
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and follow-up time. Finally, hazard ratios (HR) and 95%
confidence intervals (95% CIs) adjusted for the maximum number
of confounding variables were extracted. We preferentially focused
on cancer-specific mortality, but if these data were not available,
all-cause mortality was used instead. Relative risk estimates (RR) or
adjusted odds ratios (OR) were extracted where HR were not given
and used in meta-analysis (Symons and Moore, 2002). Study
authors were contacted to provide additional information where
needed.
Quality assessment. The methodological quality of all studies
included in the systematic review was performed using the
Newcastle-Ottawa Quality Assessment Scale (NOS; Wells et al,
2000). Two investigators (PVS and FOS) applied predefined NOS
criteria to each study to generate summary quality judgement.
The risk of bias was considered ‘low’ for studies with score of
7 or 8; ‘unclear’ for score of 5 or 6, and ‘high’ for score of 4 or
lower.
Exposure assessment. The association between circulating
25OHD and outcomes was summarised in meta-analyses by
comparing the risk in the highest to the lowest reported category.
The majority of studies used vitamin D categories such as quartiles
or tertiles. To enable inclusion of studies that used 25OHD as a
continuous variable, we sought to transform the ‘continuous HR’
into a ‘HR per 10 ngml 1’ (Box 1).
Genetic factors. For SNPs, the rs number naming convention was
typically used in the paper and some recoding was needed to
ensure that uniform reference system was followed. For example,
where a restriction fragment length polymorphism was referenced,
the mutation and risk allele were recoded (e.g., FokI f allele was
converted to the rs2228570 T allele). The genome browser
ENSEMBL (80 GRCh38.p2) was used to determine if alias names
existed (e.g., FokI, rs10735810 and rs2228570 are the same variant).
HR values were inverted where needed, so that the same allele
acted as the reference. Where additive models were used, the HR
values were squared in order to approximate the HR value for
comparison between two homozygotes.
Statistical analysis. We conducted meta-analyses for a range of
exposure-outcome pairs by cancer site and across all sites. A meta-
analysis was performed if at least two studies considered the same
exposure-outcome pair. The same study may have been included
multiple times in different meta-analyses if it reported on multiple
Table 1. ( Continued )
Variable Outcome
First author, year
Cancer
(subtype) HR/OR
Sample
Size Site
Follow-
up (m) Events NOS 25OHD Genetic
Progr-
ession Survival
Zhou et al (2006) Lung (AC, SCC) HR 373 USA 71 186 deaths 7 | OS
Xiong et al (2013) Lung (NSCC) HR 755 China NA Not given 4 | PFS OS
Newton-Bishop et al (2015) Melanoma HR 2182 UK NA Not given 6 | NS CS
Davies et al (2014) Melanoma HR 3137 Various 96 653 deaths 7 | OS
Orlow et al (2014) Melanoma HR 3566 World
wide
91 254 cancer deaths 7 | CS
Newton-Bishop et al (2009) Melanoma HR 872 UK 56 173 relapses 5 | NS DFS
Halsall et al (2004) Melanoma HR 171 UK 75 18 metastases 4 | M
Webb et al (2015) Ovarian HR 670 Australia 460 491 progression; 435
deaths
7 | BT PFS OS
Tamez et al (2009) Ovarian HR 101 Japan 85 28 cancer deaths;
total deaths not given
7 | OS
Van Loon et al (2014) Pancreatic HR 256 Europe 35 progression not
given; 254 deaths
4 | BT PFS OS
Cho et al (2013) Pancreatic HR 178 USA 33 82 deaths 5 | BT OS
Gupta et al (2015) Prostate HR 125 USA 31 49 deaths 7 | BT OS
Trummer et al (2015) Prostate HR 702 Austria 73–91 93 metastases; 123
deaths
6 | M OS
Holt et al (2013) Prostate HR 1476 USA 130 325 progression; 95
cancer deaths
7 | NS P CS
Pao et al (2013) Prostate HR 601 Taiwan 60–120 415 progression; 101
cancer deaths
8 | P CS
Fang et al (2011) Prostate HR 1822 USA 120 166 cancer deaths 8 | BD CS
Holt et al (2010) Prostate HR 1294 USA 102 139 recurrences; 57
cancer deaths
8 | R CS
Penney et al (2010) Prostate OR 1292 USA 460 Not given 5 | OS
Tretli et al (2009) Prostate HR 160 Norway 44 52 cancer deaths 6 | 77% BT CS
Williams et al (2004) Prostate HR 728 USA 60–120 Not given 7 | DFS
Renal HR 630 Europe 30 152 cancer deaths 8 | BT CS
Obara et al (2007) Renal (RCC) RR 135 Japan 460 Not given 5 | CS
Samimi et al (2014) Skin (Merkel cell) HR 89 France NA 33 metastases; 19
deaths
6 | NS M CS
Abbreviations: AC¼ adenocarcinoma; ALL¼ acute lymphocytic leukaemia; AML¼ acute myeloid leukaemia; AT 25OHD¼ assayed after cancer treatment; BCL¼B-cell lymphoma; BD
25OHD¼ assayed before diagnosis; BT 25OHD¼ assayed before treatment; CML¼ chronic myeloid leukaemia; CS¼ cancer-specific survival; DFI¼disease-free interval; DFS¼disease-free
survival; DLBCL diffuse large B-cell lymphoma; EFF¼ event-free survival; FL¼ follicular lymphoma; HCC¼Hepatocellular carcinoma; LFS¼ leaukaemia-free survival; m months; M¼metastasis;
MDS¼myelodysplastic syndrome; NA¼not available; NHL¼Non-Hodgkins lymphoma; NOS¼Newcastle-Ottawa score; NS¼Timing of 25OHD not specified/variable; NSCC¼ non-small-cell
lung carcinoma; OS¼overall-survival; P¼progression not otherwise specified; PFS¼progression-free survival; PMF¼primary myelofibrosis; R¼ recurrence or relapse not otherwise specified;
RCC¼ renal cell carcinoma; RFS¼ relapse/recurrence-free survival; SCC¼ squamous cell carcinoma; TTP¼ time to progression; TTT¼ time to treatment.
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subpopulations, outcomes, and/or exposures. The extracted HRs
and 95% CIs were used to calculate the pooled HR estimates. The
standard errors (s.e.) were used to calculate weighting for each
study. The DerSimonian and Laird random-effects model was used
to calculate pooled HR because of the a priori expected
heterogeneity between studies, due to differences among popula-
tions and methodological dissimilarities between studies; most
notably, different definition of 25OHD categories. All analyses
were performed in R (R Core Team, 2013), and the R-package
‘metafor’ was used for meta-analyses (Viechtbauer and Cheung,
2010). P-value o0.05 was considered statistically significant.
In order to assess the impact of study quality on results, meta-
analyses were rerun (i) after exclusion of studies at high risk of bias,
(ii) limited to studies at low risk of bias only, (iii) limited to studies
that looked at cancer-specific mortality, (iv) excluding studies that
used 25OHD as a continuous variable, and (v) excluding studies
that reported RR or OR. The I2 statistic was calculated to quantify
the degree of heterogeneity between studies and assess impact on
the meta-analysis (Higgins et al, 2003). To further explore this
issues arising due to the striking differences in 25OHD category
definition, we conducted a stratified analysis (Cochrane, 2011)
according to: (vi) the difference in mean/median 25OHD between
Table 2. Characteristics of studies (N¼17) included in the qualitative synthesis
Variable Outcome
First author,
year
Cancer
(subtype) Size
Follow-
up (m) Events NOS 25OHD Genetic Progression Survival Author conclusion
Reason
excluded
Obermannova et al
(2015)
Colorectal 84 24 Not given 4 | PFS OS Consistently low 25OHD
(always o16ng/ml) associated
with worse PFS and OS
Serial
25OHD
Turner et al (2013) Lung (NSCC) 142 52 Not given 7 CS Low serum DBP levels
predicted lung cancer-specific
death (P¼0.04)
Only
paper
reporting
DBP
Turna et al (2012) Lung(NSCC) 62 NA Not given 5 | OS Haplotype analysis revealed
rs731236 (TaqI)—rs2228570
(FokI) TTFf/TtFf haplotype
associated with reduced OS
(P¼0.04)
No
individual
SNP HR
Bade et al (2014) Melanoma 324 NA Not given 6 | OS Increased 25OHD (Q4 v Q1)
associated with increased OS
195 months v 80 months
(P¼0.049)
No HR
Der et al (2014) Prostate 16535 60 4613 deaths 5 | OS Vitamin D deficiency
significantly associated with
reduced survival (o0.001)
No HR
Dickinson et al (2010) Haematological
(CML)
228 NA 55 relapses;
84 deaths
5 | R OS No data provided on impact of
VDR variants
No HR
Furuya et al (1999) Prostate 66 NA Not given 3 | PFS TaqI TT genotype associated
with shorter PFS (P¼ 0.07)
No HR
Hansson et al (2014) Haematological
(AML, ALL, CML,
MDS)
123 96 29 relapses;
31 deaths
6 | R OS 25OHD o20 ng/ml associated
with reduced OS (P¼0.01) and
increased relapse (P¼ 0.03)
No HR
Kim et al (2012) Haematological 100 105 12 relapses;
4 deaths
4 | EFS OS VDR rs2228570 FokI genotype
did not impact survival in
paediatric ALL
No HR
Nurnberg et al (2009) Melanoma 205 NA 118
metastases
4 | M 25OHD 420ng/l associated
with increased time to distant
metastatic disease (P¼ 0.64)
No HR
Peiris et al (2013) Bladder 4126 NA 2025 deaths 6 | OS 25OHD o20 ng/ml associated
with reduced OS (X2¼ 10.44;
P¼ 0.001)
No HR
Silvagno et al (2010) Ovarian
(Epithelial)
26 NA Not given 2 | OS Increased platelet VDR
expression (450 fMol)
associated with increased OS
(P¼0.12)
No HR
Walentowicz-
Sadlecka et al (2012)
Ovarian 72 60 45 deaths 6 | OS 25OHD o10 ng/ml associated
with reduced OS (Po0.04)
No HR
Yagmurdur et al
(2009)
Breast 56 60 5
recurrences
3 | R rs1544410 (BsmI) genotype not
associated with local recurrence
or metastasis P40.05
No HR
Yiallourou et al (2014) Breast 87 60 Not given 3 | PFS OS rs2228570 FokI ff associated
with reduced PFS 35 months vs
454 months (P¼ 0.08)
No HR
Field et al (2013) Melanoma 795 56 137 cancer
deaths
4 | CS 8ng/ml incremental increase in
25OHD associated with
improved DFS (P¼ 0.02) and
MSS (P¼ 0.05)
Duplicate
patient
cohort
Vrieling et al (2011) Breast 1295 70 182
recurrence
or
metastases;
183 deaths
7 | DFS OS Low 25OHD significantly
associated with worse DFS and
OS
Duplicate
patient
cohort
Abbreviations: AML¼ acute myeloid leukaemia, ALL¼ acute lymphocytic leukaemia; CML¼ chronic myeloid leukaemia; CS¼ cancer-specific survival; DFS¼disease-free survival; DBP¼ vitamin
D binding protein; EFF¼ event-free survival; fMol¼ femtomol; HR¼ hazard ratio; m¼months; M¼metastasis; MDS¼myelodysplastic syndrome; MSS¼melanoma specific survival; NOS¼
Newcastle-Ottawa score; NSCC¼non-small-cell lung carcinoma; OS¼overall survival; PFS¼progression-free survival; R¼ recurrence or relapse not otherwise specified; SNP¼ single
nucleotide polymorphism.
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‘high’ and ‘low’ categories compared (below orX20 ngml 1), and
(vii) the degree of deficiency in ‘low’ category (mean/median
25OHD concentration below or X12.5 ngml 1). Publication and
selection bias was investigated by checking for asymmetry in the
funnel plots and running the Egger’s regression test (Sterne and
Egger, 2001).
RESULTS
A flowchart illustrating study selection is shown in Figure 1. After
removal of duplicates, the search yielded 3070 potential articles.
Irrelevant articles were eliminated after screening titles (N¼ 2708)
Author Comparision 0 12.5 25 37.5 50
250HD (ng ml–1)
62.5 75 87.5 100
0 12.5 25 37.5 50
25-hydoxyvitamin D level ng ml–1
Catagory/cohort median (reported)
Catagory/cohort median (approximated)
Cohort mean (reported)
Range of category values
Cut off of category values (range not given)
250HD continuous
62.5 7.5 87.5 100
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quintile 4 vs Quintile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Tertile 3 vs Tertile 1
Tertile 3 vs Tertile 1
Tertile 3 vs Tertile 1 NA
NA
NA
< >8 ng ml–1
< >20 ng ml–1
< >20 ng ml–1
< >20 ng ml–1
< >20 ng ml–1
< >20 ng ml–1
< >20 ng ml–1
< >25 ng ml–1
< >25 ng ml–1
< >25 ng ml–1
< >30 ng ml–1
< >30 ng ml–1
Continuous (range NA)
Continuous
Continuous
Continuous
20–30 vs < 10 ng ml–1
20–59.9 vs < 12 ng ml–1
>20 and < 16 ng ml–1
>29 vs <20 ng ml–1
>30 vs <20 ng ml–1
>30 vs <20 ng ml–1
>32 vs <20 ng ml–1
>32 vs <20 ng ml–1
>32 vs <20 ng ml–1
>20 vs  10 ng ml–1
20–60 vs <20 ng ml–1
Mezawa
Zgaga
Bittenbring
Webb
Finkelmeier
Liu
Zhou
Holt
Heist
Ng (2011)
Vrieling
Fedirko
Lohmann
Tretli (2012)B
Tretli (2012)L
Tretli (2012)Ly
Meyer
Samimi
Lim
Ren
Jacobs
Aref
Cho
Newton-Bishop
(2015)
Goodwin
Kim
Villasenor
Lee
Tretli (2009)
Tretli (2012)C
Ng (2008)
Drake
Pardanani
Shanafelt
Wesa
Hatse
Clark
Gugatschka
Newton-Bishop
(2009)
Van Loon
Kelly
Fang
Muller
Gupta
Legend
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or abstracts (N¼ 262). One hundred full-texts were considered for
inclusion and assessed for eligibility and 19 were excluded. Finally,
81 articles were kept for the systematic review and 64 of these were
included in the meta-analysis. The main characteristics of included
studies are summarised in Table 1 and Table 2.
Assessment of included studies. The risk of bias assessment
revealed that 35 studies (43%) had a low risk of bias, 35 (43%) had
an uncertain, and 11 (14%) had a high risk of bias. The risk of bias
assessment summary per each domain is shown in Supplementary
Figure S1 and individual study scores in Supplementary Figure S2.
Sixty-four studies were included in the meta-analysis, with a total
of 44 165 patients. Most studies were conducted in the USA
(N¼ 24) and Europe; breast cancer was most commonly studied
(N¼ 15), followed by nine studies (each) on prostate cancer and
colorectal cancer. In total, 157 HR estimates for a range of
exposure-outcome pairs were included in meta-analyses: 77
estimates (from 41 studies) for association with 25OHD, and
80 estimates (from 27 studies) relating to genetic factors. Separate
estimates were extracted for different patient subgroups (e.g.,
different type of haematological malignancy (Drake et al, 2010)),
different exposures (e.g., multiple polymorphisms (Zgaga et al,
2014)), or different outcome (i.e., survival or disease progression
(Lohmann et al, 2015)). No patients were included more than once
in meta-analysis, as separate meta-analyses have been conducted
for each exposure-outcome pair. Very large differences were
observed in definition of vitamin D categories being compared. For
example, the median 25OHD concentration was 18.26 ngml 1 in
the ‘high’ category in one study, (Zgaga et al, 2014) yet this was
actually lower than the median (19.7 ngml 1) in the ‘low’ category
in another study (Hatse et al, 2012). The variety of vitamin D
categories, cutoffs and means/medians used are presented in
Figure 2 and Supplementary Figure S3.
Meta-analysis of 25OHD studies
Circulating vitamin D and survival. Forty-eight estimates from
38 studies were included in the meta-analysis of 25OHD and
survival (17 studies (45%) examined cancer-specific mortality),
comprising in total 24 013 cancer patients. Twelve cancer types
were represented: breast, haematological, head and neck, colorectal,
lung, prostate, skin, pancreatic liver, gastric, kidney and ovarian
cancers. Overall, a significantly reduced risk of death was observed
when comparing those with high to those with low vitamin D
levels; meta-analysis HR¼ 0.74, 95% CI¼ 0.66 to 0.82 (Figure 3).
The same significant trend was also observed in subgroup meta-
analysis for breast (HR¼ 0.75, 95% CI¼ 0.56–0.95), haematologi-
cal (HR¼ 0.59, 95% CI¼ 0.42–0.77) and colorectal cancers
(HR¼ 0.75, 95% CI¼ 0.60–0.90). There was also a non-significant
trend towards better survival with increased 25OHD observed in
the subgroup analysis for prostate, skin, head and neck cancers.
Virtually no change in direction or significance in overall effect was
observed in sensitivity analyses when excluding studies at high risk
of bias (HR¼ 0.73, 95% CI¼ 0.65–0.80), focusing on the studies at
low risk of bias only (HR¼ 0.72, 95% CI¼ 0.63–0.81), excluding
studies that used continuous 25OHD (HR¼ 0.73, 95% CI¼ 0.65–
0.80), limited to cancer-specific mortality studies only (HR¼ 0.75,
95% CI¼ 0.65–0.84), or to studies that strictly reported HR
(HR¼ 0.74, 95% CI¼ 0.66–0.82). The same was true after selection
of studies where the difference in mean/median between high and
low categories being compared was over or below 20 ngml 1;
(HR¼ 0.70, 95% CI¼ 0.60–0.81, and HR¼ 0.71, 95% CI¼ 0.55–
0.87, respectively), or when stratifying by the lower category mean/
median below or greater than 12.5 ngml 1 (HR¼ 0.76, 95%
CI¼ 0.64–0.88, and HR¼ 0.61, 95% CI¼ 0.47–0.75, respectively)
(for sensitivity analysis please see supplementary material).
The relationship between circulating vitamin D level and disease
progression. Twenty-three studies investigated the association
between circulating 25OHD and disease progression; from these
studies 29 estimates were included in our meta-analysis comprising
in total 14 307 patients with breast, haematological, head and neck,
colorectal, prostate, skin, pancreatic, or ovarian cancer. Higher
circulating vitamin D was associated with a significant reduction in
disease progression for all cancers combined (HR¼ 0.84, 95%
CI¼ 0.77–0.91; Figure 4); this was also observed in subgroup meta-
analysis of breast (HR¼ 0.66, 95% CI¼ 0.45–0.88), haematological
(HR¼ 0.75, 95% CI¼ 0.61–0.88) and skin cancer (HR¼ 0.77, 95%
CI¼ 0.58–0.97). Findings remain fundamentally unchanged after
exclusion of studies at high risk of bias (HR¼ 0.82, 95% CI¼ 0.74–
0.90), limited to studies at low risk of bias only (HR¼ 0.80, 95%
CI¼ 0.70–0.90) or excluding studies that used continuous 25OHD
(HR¼ 0.81, 95% CI¼ 0.73–0.90), or limited to studies that strictly
reported HR (HR¼ 0.84, 95% CI¼ 0.77–0.91). The same was true
after selection of studies where the difference in mean/median
between high and low categories being compared was over or
below 20 ngml 1; (HR¼ 0.81, 95% CI¼ 0.72–0.90, and
HR¼ 0.75, 95% CI¼ 0.55–0.95, respectively), or when stratifying
by the lower category mean/median below or greater than
12.5 ngml 1 (HR¼ 0.84, 95% CI¼ 0.71–0.97, and HR¼ 0.77,
95% CI¼ 0.62–0.92, respectively) (for sensitivity analysis please see
supplementary material).
Vitamin-D-related genetic variation
VDR and other vitamin D pathway SNPs and survival. Twenty-
one studies investigated the association between vitamin-D-related
genetic variation and survival; 10 (48%) examined cancer-specific
Figure 2. Large variation in definition of vitamin D categories in studies included in systematic review. Where not given in the paper, median
25OHD concentration for categories compared was requested from study authors and if not subsequently available was approximated.
Approximation of the median for each category was performed using the cohort and/or category range where available. For categories defined by
numerical cutoffs of 25OHD, the median for the lower category was approximated as the lowest reported 25OHD value (or 0 if category range not
given) added to the midpoint of the category upper cutoff minus the lowest reported 25OHD value. For example, Bittenbring et al (Bittenbring
et al, 2014) reported outcome according to 25OHDo48 ngml1 groups and reported a study cohort range of 4–61.9. The median of the lower
category (o8 ngml1) was approximated as the lowest value in the range plus the midpoint of the category that is, 4þ ((84)/2)¼6. The upper
category median was approximated as the category cutoff (that is, the lowest value in that category) added to the midpoint of the lower category.
for example, in the Bittenbring et al, paper the median of the upper category was approximated as 8þ ((84)/2)¼10. Where the compared
categories were tertiles, quartiles or quintiles, the median of the lower category and upper categories was the midpoint of the difference between
upper cutoff of the lower category compared and the lower cut-off of the higher category compared divided by the number of groups between
two categories compared, either subtracted from the upper cutoff of the lower category or added to the lower cutoff of the higher category,
respectively. For example, Bade et al, (Bade et al, 2014) grouped patients by quartile of 25OHD and report a cohort range of 4–59.6 ngml 1.
Q1 is given as 25OHDo9.86ngml 1 and Q4 424.4 ngml 1. Therefore, the medians of Q1 and Q4 were approximated as follows:
Q1(median)¼ 9.86 (((24.49.86)/2)/2)¼6.225 and Q4(median)¼24.4þ (((24.4 9.86)/2)/2)¼ 28. Insufficient data were reported in three
studies to allow graphical illustration of categories or approximation of median. NA¼data not reported; For Tretli et al, study: B¼breast;
C¼ colon; L¼ lung; Ly¼ lymphoma.
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Adjusted meta-analysis: survival for circulating 25(OH)D
Author and Year Population N.O. score N Exposure (ng ml–1)
Breast
Hatse, 2012 Belgium
USA
USA
USA
USA
USA
USA
USA
USA
USA
Norway
Egypt
Egypt
USA
USA
USA
USA
USA
USA
Europe
Norway
Germany
Canada
Norway
USA
Canada
Korea
Germany
Villasenor, 2013
Goodwin, 2009
Tretli, 2012
Jacobs, 2011
Lohmann, 2015
Lim, 2015
Vrieling, 2014
Subtotal (breast)
Haemotological
Lee, 2014
Shanafelt, 2011
Drake (PostFL), 2010
Drake (FL), 2010
Drake (MCL), 2010
Drake (TCL), 2010
Drake (DLBCL), 2010
Drake (other), 2010
Tretli, 2012
Aref (CLL), 2013
Aref (NHL), 2013
Pardanani (MDS), 2011
Pardanani (PMF), 2011
Kelly (Swog cohort), 2015
Kelly (Lysa cohort), 2015
Bittenbring, 2014
Subtotal,(Haemotological)
Colorectal
Wesa,2015
Fedirko et al, 2012
Tretli, 2012
Ng, 2011
UK
USA
Zgaga,2014
Ng, 2008
Japan
Norway
China
USA
USA
USA
USA
USA
USA
France
UK
Germany
China
Czech Republic
Australia
Norway
USA
Canada
Austria
5
7
4
8
7
7
7
7
7
7
8
6
6
5
5
7
7
5
6
8
8
5
7
8
7
5
8
7
8
7
5
8
6
7
7
7
7
5
4
6
6
6
6
8
8
6
8
8
4
HR (95% CI)
0.49 ( 0.27 , 0.89 )
1.21 ( 0.52 , 2.80 )
0.34 ( 0.16 , 0.72 )
0.68 ( 0.45 , 1.03 )
0.36 ( 0.08 , 1.72 )
1.11 ( 0.29 , 4.35 )
0.74 ( 0.29 , 1.89 )
0.44 ( 0.19 , 1.01 )
0.46 ( 0.28 , 0.75 )
0.58 ( 0.19 , 1.72 )
0.39 ( 0.18 , 0.83 )
0.19 ( 0.04 , 0.86 )
0.24 ( 0.07 , 0.85 )
0.71 ( 0.37 , 1.43 )
0.83 ( 0.63 , 1.25 )
0.35 ( 0.10 , 1.16 )
0.19 ( 0.04 , 0.90 )
0.61 ( 0.38 , 0.98 )
0.94 ( 0.72 , 1.23 )
0.69 ( 0.50 , 0.93 )
0.20 ( 0.04 , 1.10 )
0.56 ( 0.30 , 0.90 )
0.59 ( 0.42 , 0.77 )
0.63 ( 0.38 , 1.04 )
0.42 ( 0.21 , 0.82 )
0.88 ( 0.56 , 1.39 )
1.07 ( 0.57 , 2.02 )
0.46 ( 0.17 , 1.22 )
0.79 ( 0.53 , 1.16 )
0.75 ( 0.56 , 0.95 )
0.68 ( 0.50 , 0.90 )
0.61 ( 0.31 , 1.19 )
0.82 ( 0.23 , 2.94 )
0.75 ( 0.60 , 0.90 )
0.18 ( 0.11 , 0.29 )
2.54 ( 1.01 , 6.41 )
0.74 ( 0.50 , 1.10 )
1.08 ( 0.75 , 1.57 )
1.07 ( 0.17 , 1.98 )
0.83 ( 0.37 , 2.00 )
0.71 ( 0.31 , 1.42 )
0.50 ( 0.29 , 0.87 )
0.83 ( 0.36 , 1.29 )
1.00 ( 0.88 , 1.14 )
0.19 ( 0.03 , 1.30 )
0.66 ( 0.41 , 1.03 )
0.64 ( 0.20 , 1.07 )
0.50 ( 0.28 , 0.88 )
0.59 ( 0.37 , 0.91 )
0.70 ( 0.39 , 1.24 )
0.69 ( 0.51 , 0.93 )
0.74 ( 0.66 , 0.82 )
0.09 ( 0.03 , 0.27 )
0.90 ( 0.72 , 1.15 )
0.84 ( 0.63 , 1.06 )
0.85 ( 0.57 , 1.28 )
0.31 ( 0.10 , 0.97 )
0.79 ( 0.40 , 1.17 )
Weight
1.6%
0.9%
1.1%
3.0%
0.3%
0.3%
0.7%
0.9%
2.3%
0.5%
1.0%
0.3%
0.4%
1.2%
3.0%
0.4%
0.3%
2.4%
5.5%
4.8%
0.2%
2.4%
2.2%
1.3%
2.5%
1.4%
0.6%
3.3%
5.2%
1.3%
0.4%
2.4%
0.7%
3.2%
3.5%
0.8%
1.2%
1.8%
10.7%
0.2%
2.6%
1.8%
2.8%
1.7%
4.8%
0.5%
6.2%
3.0%
0.5%
1800
585
97
543
109
285
71
70
370
78
145
120
75
74
247
183
240
250
515
1202
52
359
512
251
512
934
491
2177
1598
304
257
210
568
447
294
1476
125
178
256
89
1557
200
197
630
670
Hazard ratio
0.00 1.50 3.00 4.50
160
1822
540
88
>30 vs <30
>30 vs <30
>32 vs <20
>25 vs <25
>25 vs <25
>25 vs <25
>25 vs <25
>25 vs <25
>25 vs <25
>25 vs <25
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 5 vs Quartile 1
>20 vs <20
>20 vs <20
>25 vs <25
>25 vs <25
Tertile 3 vs Tertile 1
Tertile 3 vs Tertile 1
Tertile 3 vs Tertile 1
>8 vs <8
>30 vs <20
>29 vs <20
Quartile 4 vs Quartile 1
>30 vs <10
>20 vs <16
>20 vs <20
Tertile 3 vs tertile 1
Per 10 ng ml–1 increase
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Quartile 4 vs Quartile 1
Per 10 ng ml–1 increase
Per 10 ng ml–1 increase
>20 vs <12
>32 vs <20
>20 vs <20
>20 vs <20
>8 vs <8
>10 vs <10
>20 vs <20
>20 vs <10
>32 vs <20
Mezawa,2010
Subtotal (Colorectal)
Lung
Tretli,2012
Liu,2011
Zhou,2007
Heist,2008
Subtotal (Lung)
Head and Neck
Meyer, 2011
Gugats chka, 2011
Holt, 2013
Gupta, 2015
Tretli, 2009
Fang, 2011
Cho, 2013
Van Loon, 2014
Samimi, 2014
Newton-Bishop, 2015
Finkelmeier, 2014
Subtotal (Skin)
Liver
Ren, 2012
Gastric
Muller, 2015
Kidney
Webb, 2015
Ovarian
OVERALL CANCER
Subtotal (Pancreatic)
Skin
Subtotal (Head and Neck)
Prostate
Pancreatic
Subtotal(Prostate)
Figure 3. Cancer survival and 25-hydroxyvitamin D concentration: meta-analysis of adjusted hazard ratios. HR are sorted by cancer site and the
difference in median between ‘high’ and ‘low’ vitamin D categories compared. Acute myeloid leukaemia (AML), Chronic Lymphoid Leukaemia
(CLL), and subtypes of non- Hodgkin’s lymphoma (NHL) (large B-cell lymphoma (DLBCL), T-cell lymphoma (TCL), Follicular Lymphoma (FL) and
mantle cell lymphoma (MCL)) Myelodysplastic syndrome (MDS) and primary myelofibrosis (PMF). I2¼breast: 0, haematological: 0, colorectal: 0.91,
prostate: 0.68, head and neck: 0, pancreatic: 0.66, lung: 0.93, skin: 0, overall cancer: 0.18. Approximated Median in studies using quartiles/tertiles
(ngml1): Tretli breast (lower: 12.9, upper: 33.9), Tretli Haematological: (lower:14.3, upper: 34.1), Tretli colorectal: (lower:16.4, upper: 38), Tretli
lung: (lower:14.3, upper: 34.1), Vrieling: (lower: 10.6, upper: NA), Kelly (NA), Fedirko: (lower:11.8, upper: 33.4), Ng et al (2011): (lower:9.6, upper:
30.7), Zgaga: (lower:4.4, upper: 18.3), Ng et al (2008): (lower:21, upper: 30.6), Liu: (lower:7, upper: 25.4), Zhou: (lower:7.4, upper: 24.5), Heist:
(lower:10.4, upper: 23.9), Meyer: (lower:16.2, upper: 34.2), Fang: (NA), Muller: (NA).
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mortality. By far, the most commonly studied were polymorphisms
in VDR gene, particularly rs2228570 (FokI), rs1544410 (BsmI),
rs731236 (TaqI), rs11568820 (Cdx2), and rs7975232 (ApaI). In
meta-analysis, rs1544410 TT/TC genotypes were associated with
worse survival compared to CC genotype (HR¼ 1.40, 95%
CI¼ 1.05–1.75; Figure 5). The same direction of the effect was
observed in the sensitivity analyses after exclusion of studies with
NOSo7 (Supplementary Figure S4) and those reporting on
cancer-specific mortality, but the association was no longer
significant (Supplementary Figure S5). In lung cancer patients, a
poorer outcome was observed to be associated with rs2228570 TT/
TC carriers (HR¼ 1.29, 95% CI¼ 1.00–1.57) and a consistent
albeit non-significant association was found across all cancers
(HR¼ 1.26, 95% CI¼ 0.96–1.56). A significant association was
observed with rs731236 (Taq1) variant when limited to studies at
low risk of bias (NOS score X7; HR¼ 0.79, 95% CI¼ 0.62–0.95,
Supplementary Figure S4). Other genetic factors were investigated
in at most three original studies and no other statistically
significant results were observed.
VDR and vitamin D pathway SNPs and disease progression. Ten
studies examined the effect of genetic variation on disease
progression (Figure 6; for sensitivity analysis see Supplementary
Figure S6). In meta-analysis of three studies with a total of 1588
patients, it was observed that rs7975232 AA carriers had
significantly worse survival than CC carriers (HR¼ 1.29, 95%
CI¼ 1.02–1.56). Additionally, a suggestive association was
observed for vitamin D binding protein variant rs2282679
(HR¼ 1.22, 95% CI¼ 0.99–1.46) in meta-analysis of two studies.
Testing for publication bias and study heterogeneity. There was
some evidence of heterogeneity between studies in meta-analysis of
25OHD and some evidence of publication bias (Supplementary
Figures S7 and S8). A non-insignificant degree of heterogeneity
and evidence of publication bias were observed in some subgroup
analysis. Heterogeneity was observed for subgroup analysis of
rs1544410, rs7975232, rs2228570 and rs731236, as well as for some
individual cancer types while publication bias was observed for
rs1544410, rs2228570 and rs731236 (Supplementary Figures S7
and S8).
Studies not included in meta-analysis. Seventeen papers were
excluded from the meta-analysis, but their findings were none-
theless considered (Table 2). Eight studies report improved overall
and/or progression-free survival among those with higher 25OHD
concentration (Vrieling et al, 2011; Walentowicz-Sadlecka et al,
2012; Peiris et al, 2013; Field et al, 2013; Bade et al, 2014; Der et al,
Adjusted Meta-analysis: Disease progression for circulating 25(OH)D
Author(s) and Year
Breast
Hatse, 2012
Goodwin, 2009
Kim, 2011
Jacobs, 2011
Lohmann, 2015
Lim, 2015
Vrieling, 2014
Clark, 2014
Subtotal (Breast)
Haemotological
Lee, 2014
Shanafelt, 2011
Drake (PostFL), 2010
Drake (FL), 2010
Drake (MCL), 2010
Drake (TCL), 2010
Drake (DLBCL), 2010
Drake (other), 2010
Pardanani (MDS), 2011
Pardanani (PMF), 2011
Kelly (Swog cohort), 2015
Kelly (Lysa cohort), 2015
Bittenbring, 2014
Subtotal (Haemotological)
Subtotal (Head and Neck)
Subtotal (Colon)
Subtotal (Skin)
Head and Neck
Colorectal
Prostate
Skin
Pancreatic
Ovarian
OVERALL CANCER
Samimi, 2014
Newton-Bishop, 2009
Van Loon, 2014
Webb, 2015
Holt, 2013
Ng, 2011
Mezawa, 2010
Meyer, 2011
Gugatschka, 2011
Belgium
Canada
Korea
USA
Canada
Korea
Germany
USA
USA
USA
USA
USA
USA
USA
USA
USA
USA
USA
USA
USA
Germany
France
UK
USA
Australia
USA
USA
Japan
Canada
Austria
5
7
7
7
5
8
7
5
4
8
7
7
7
7
7
7
5
5
7
7
5
6
5
4
8
7
8
5
8
4
1800
512
310
512
934
491
2177
82
97
543
109
285
71
70
370
78
74
247
183
240
359
89
872
256
670
14,307
1476
515
257
540
88
0.58 ( 0.35 , 0.98 )
0.25 ( 0.09 , 0.70 )
HR (95% CI)
0.25 ( 0.11 , 0.56 )
0.88 ( 0.43 , 1.75 )
1.14 ( 0.65 , 1.99 )
0.45 ( 0.25 , 1.99 )
0.57 ( 0.40 , 0.81 )
0.77 ( 0.34 , 1.75 )
0.66 ( 0.45 , 0.88 )
0.39 ( 0.19 , 0.78 )
0.68 ( 0.51 , 0.90 )
1.02 ( 0.53 , 1.96 )
0.93 ( 0.62 , 1.41 )
0.92 ( 0.50 , 1.69 )
0.52 ( 0.28 , 0.96 )
0.71 ( 0.49 , 1.02 )
0.87 ( 0.43 , 1.75 )
0.77 ( 0.25 , 3.30 )
0.83 ( 0.63 , 1.25 )
0.76 ( 0.40 , 1.45 )
0.65 ( 0.37 , 1.16 )
0.71 ( 0.47 , 1.10 )
0.75 ( 0.61 , 0.88 )
0.34 ( 0.12 , 0.97 )
0.79 ( 0.64 , 0.96 )
0.77 ( 0.58 , 0.97 )
1.00 ( 0.82 , 1.20 )
0.87 ( 0.60 , 1.13 )
0.84 ( 0.77 , 0.91 )
0.91 ( 0.83 , 1.10 )
1.07 ( 0.81 , 1.42 )
1.22 ( 0.45 , 3.30 )
1.08 ( 0.81 , 1.35 )
1.12 ( 0.65 , 1.93 )
0.20 ( 0.04 , 0.98 )
0.98 ( 0.33 , 1.63 )
>30 vs <30
Population N.O. Score N Exposure (ng ml–1)
>29 vs <20
>30 vs <20
>30 vs <10
>20 vs <16
>20 vs <20
Tertile 3 vs Tertile 1
>20 vs <20
>32 vs <20
>25 vs <25
>25 vs <25
>25 vs <25
>25 vs <25
>25 vs <25
>25 vs <25
>25 vs <25
>25 vs <25
>25 vs <25
Tertile 3 vs Tertile 1
Tertile 3 vs Tertile 1
>8 vs <8
>20 vs <20
per 8 increase
Per 10 ng ml–1 increase
>20 vs <10
0.00 1.00
Hazards ratio
2.00
>20 vs <20
Quartile 4 vs Quartile 1
Per 10 ng ml–1 increase
Quartile 4 vs Quartile 1
Per 10 ng ml–1 increase
Weight
0.5%
1.9%
0.8%
1.1%
1.7%
0.2%
4.3%
0.8%
1.1%
6.7%
1.2%
3.0%
1.4%
1.4%
4.0%
1.1%
0.2%
3.1%
1.3%
1.6%
2.7%
0.5%
13.8%
15.8%
7.7%
13.0%
6.6%
0.5%
1.8%
0.2%
Figure 4. Cancer progression and 25-hydroxyvitamin D concentration: meta-analysis of adjusted hazard ratios. HR are sortd by the difference in
median between high and low vitamin D levels compared. Acute myeloid leukaemia (AML), Chronic Lymphoid Leukaemia (CLL), and subtypes of
non- Hodgkin’s lymphoma (NHL) (large B-cell lymphoma (DLBCL), T-cell lymphoma (TCL), follicular lymphoma (FL) and mantle cell lymphoma
(MCL)). I2¼breast: 0, haematological: 0, colorectal: 0, head and neck: 0, skin: 0 overall cancer: 0. Approximated median in studies using quartiles/
tertiles (ngml1): Vrieling: (lower: 10.6, upper: NA), Kelly (NA), Meyer: (lower:16.2, upper: 34.2), Ng et al, (2011): (lower:9.6, upper: 30.7).
BRITISH JOURNAL OF CANCER Vitamin D and cancer outcome: a review
10 www.bjcancer.com |DOI:10.1038/bjc.2017.44
2014; Hansson et al, 2014; Obermannova et al, 2015) and one
study found no association between 25OHD and incidence of
metastases (Nurnberg et al, 2009). Seven studies investigated
genetic variants and outcome (median sample size: 66). One study
reported that the rs731236/rs2228570 (TaqI-FokI, TTFf/TtFf)
haplotype was significantly associated with reduced overall survival
(HR¼ 1.81, 95% CI¼ 1.23–3.48, P¼ 0.04) (Turna et al, 2012):
suggestive associations were reported between progression-free
survival and rs731236 (AA) genotype in prostate cancer (Furuya
et al, 1999) and rs2228570 TT genotype in breast cancer
(Yiallourou et al, 2014), while there was no association found
between rs2228570 and paediatric ALL (Kim et al, 2012). No
association was observed between rs1544410 and breast cancer
outcome (Yagmurdur et al, 2009). There was a suggestive
association between platelet VDR expression and survival in
ovarian cancer (Silvagno et al, 2010). Finally, low vitamin D
binding protein (DBP) levels were found to be predictive of lung
cancer death (Turner et al, 2013).
Adjusted Meta-analysis: Survival for Vitamin D receptor and pathway polymorphisms
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DISCUSSION
This is the first systematic review with meta-analysis that examines
the relationship between cancer outcomes and variation in vitamin D
pathway genes, and also by far the largest review on vitamin D status
and cancer outcome. Our review suggests that higher circulating
vitamin D in cancer patients is associated with a 26% lower rate of
death and a 16% lower rate of disease progression. The clear
association with survival was also observed in site-specific analyses of
breast, haematological and colorectal cancers, while an association
with reduction in disease progression was also found in those
diagnosed with breast, haematological and skin cancer.
Establishing a causal relationship between vitamin D status and
cancer progression is challenging because risk factors associated
with cancer outcome are often also associated with vitamin D
deficiency. For example, the association between 25OHD and
improved survival observed in the original studies might be due to
25OHD being a marker of healthier lifestyle (i.e., healthier diet
containing more fish; physical activity and spending time
outdoors). However, evidence that genetic factors linked to vitamin
D metabolism and pathways impact upon cancer survival may be
used to counter such concerns and support a causal link. In our
meta-analysis, we found evidence of an association between the
VDR gene variants with functionally characterised effects and
cancer outcome. Forty percent higher rate of death was observed in
TT carriers at rs1544410 locus and 26% higher rate in TT carriers
at rs2228570, while 29% increased risk of disease progression was
observed in AA carriers at rs7975232 and 22% in GG carriers at GC
locus.
Evidence from biological studies support a role for these
polymorphisms in modulating vitamin D biology. For example,
rs2228570 has been shown to affect the translational start site of
1,25(OH)2D and hence its downstream effects (Uitterlinden et al,
2004), while rs1544410 and rs7975232 have been associated with
changes in VDR messenger RNA expression (Staal et al, 1996;
Uitterlinden et al, 2004). We hypothesise that interactions between
mutations in the vitamin D pathway and vitamin D status exist,
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and that this interaction could have a critical role in cancer
prognosis. Indeed, Han et al (Han et al, 2007) have shown an
interaction between vitamin D intake and rs1544410 polymorph-
ism on cancer risk, and we and others have previously shown a
modification of the relationship between vitamin D intake or status
and cancer outcome by other VDR variants, thus suggesting an
interaction of genetic and environmental factors (Li et al, 2007;
Theodoratou et al, 2008; Anderson et al, 2011; Zgaga et al, 2014).
In conjunction with the strong associations observed for vitamin D
status, evidence from genetic studies further supports an important
role of vitamin D in cancer progression.
Few studies to date have analysed the associations between VDR
or vitamin D pathway genetic variants and cancer outcomes, and
no meta-analyses have been published to date. A review by Kostner
et al (Kostner et al, 2009) concluded that associations between
VDR polymorphisms and cancer prognosis are strongest for
prostate cancer (rs2228570), breast cancer (rs1544410, rs731236)
malignant melanoma (rs1544410), and renal cell carcinoma
(rs731236) but did not perform meta-analysis on these data.
Interestingly, Afzal et al (Afzal et al, 2014) have employed
principles of Mendelian randomization in a study comprising 95 766
participants and found that variation in genes involved in vitamin D
and 25OHD synthesis (DHCR7 and CYP2R1) were associated with
both all-cause and cancer mortality, supporting a causal role of
vitamin D. To date, there are no published findings from
randomised controlled trials (RCT) assessing the effect of vitamin
D supplementation on survival in cancer patients, although several
ongoing trials (unfortunately only some of which have disease
progression as an outcome) were identified (ClinicalTrials.gov,
2016). Meanwhile, the data on cancer mortality from RCTs
conducted in the general population can offer some insight; most
notably, a Cochrane review of randomised studies comparing
vitamin D supplements to placebo identified a significant reduction
in cancer mortality in those taking vitamin D supplements
(HR¼ 0.88, 95% CI¼ 0.78–0.98; Bjelakovic et al, 2014).
A major issue that is typically taken poor notice of in vitamin D
meta-analyses—namely, a very large variability in vitamin D
category definition amongst studies, is for the first time being
highlighted and transparently shown in our review. Vitamin D
categories differed in level as well as range—as a result, large
heterogeneity in exposure definition occurred and study point-
estimates are difficult to compare: it is, for example, unsurprising
that the reported effect per 20 ngml 1 is greater than effect per
5 ngml 1 increase. Therefore, there is a need for a consensus in
category definition and reporting of effect sizes: future original
studies should report effect sizes using internationally agreed
cutoffs, such as those given by the Institute of Medicine, solely or
in addition to study-specific cutoff values chosen. Generally,
variability in exposure categories results in a more heterogeneous
estimates and is likely to increase statistical uncertainty and hence
bias results towards the null. Nonetheless, our summary findings
remain largely unchanged when the analysis was limited according
to the difference in 25OHD between the compared groups.
There are some additional limitations of the present work. First,
a number of relevant studies were published after the time limits
stipulated in our search strategy and so are not included in our
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meta-analysis. Some such papers support the conclusions pre-
sented here (Brandstedt et al, 2016; Fang et al, 2016; Fanidi et al,
2016; Mondul et al, 2016; Orlow et al, 2016; Yao et al, 2016; Yuan
et al, 2016), while others reported no association between
circulating vitamin D and cancer outcome (Vashi et al, 2015;
Ahn et al, 2016; Danilovic et al, 2016; McGovern et al, 2016).
Adjusted meta-analysis: disease progression for vitamin D receptor and pathway polymorphisms
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Second, various assays were used for 25OHD measurement in
the different studies, while 25OHD was also sampled at variable
timepoints, including pre-diagnosis, before treatment and after
treatment, which may impact the results. Also, in disease
progression studies, different outcome definitions were used for
example, disease-free survival, local or distant recurrence.
In the present study, results for all cancers combined are given,
in addition to site-specific findings, we yet fully acknowledge that
cancer is a heterogeneous disease. However, numerous studies have
shown involvement of vitamin D on key hallmarks of cancer, many
of which are common to all cancers; preclinical studies
demonstrate effects on cell cycle arrest, cell adhesion, differentia-
tion, proliferation, tumour angiogenesis, and apoptosis in human
cancer cell lines (Simboli-Campbell et al, 1997; Chen et al, 2000;
Krishnan et al, 2003; Deeb et al, 2007; Kizildag et al, 2010; Hsu
et al, 2011; Ting et al, 2012), while reduction in cancer proliferation
has been shown in carcinogen-exposed rats (Mokady et al, 2000)
and cancer phenotypes are more commonly observed in vitamin D
receptor (VDR) knockout mice (Zheng et al, 2012). Nevertheless,
the heterogeneity in pooled results between different cancer types
and the small number of studies for certain cancers limits the
strength of the current study in demonstrating an association
between circulating 25-hydroxyvitamin D and total cancer survival.
Next, in reporting the impact of genetic variation on outcome,
we acknowledge that ethnic differences in VDR variation exist,
which might interfere with the findings from genetic studies, as
ethnicity is directly linked to the skin type and vitamin D synthesis.
Meanwhile, VDR variants may interact with circulating 25OHD to
impact outcome, yet only a small number of studies examined
these putative gene–environment interactions. Finally, we observed
some evidence of heterogeneity and publication bias overall;
however, findings from sensitivity analysis were highly consistent
and supportive of main findings.
Despite these limitations, the present work includes a novel
meta-analysis, investigating the association between vitamin
D-related genetic variation and cancer outcome, in addition to a
B50% larger meta-analysis of circulating 25OHD and cancer
outcome compared to a previous review (Li et al, 2014). Moreover,
stringent quality assessment of original studies and corresponding
sensitivity analysis were conducted and strikingly inconsistent
25OHD category definitions were addressed in stratified analysis.
In conclusion, the consistent evidence across the studies
presented in the current review demonstrates a clear and strong
association between low baseline vitamin D levels and poorer
cancer survival. The associations between vitamin D-related
genetic variants and cancer survival support an interpretation that
vitamin D may play an important role in influencing cancer
outcome. However, a causal link cannot be conclusively established
from observational studies; hence, well-designed and adequately
powered RCTs are needed to evaluate the clinical application of
vitamin D in augmenting standard follow-up and adjuvant
chemotherapy regimens. Understanding the mechanism of action
of genetic factors promises to provide further insight into
biological determinants of response to treatment and could help
inform prognosis.
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